11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy

Neurology

Volumn 49, Issue 3, 1997, Pages 764-773

  Koepp, M J ^a,b   Richardson, M P ^a,b   Labbe C ^a   Brooks, D J ^a   Cunningham, V J ^a   Ashburner, J ^a   Van Paesschen, W ^b   Revesz, T ^b   Duncan, J S ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE RECEPTOR; CARBAMAZEPINE; CARBON 11; FLUMAZENIL; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; CARBON; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; FEMALE; HIPPOCAMPUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SCLEROSIS; TEMPORAL LOBE EPILEPSY; TREATMENT OUTCOME; BRAIN DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; BRAIN DISEASES; CARBON RADIOISOTOPES; EPILEPSY, TEMPORAL LOBE; FEMALE; FLUMAZENIL; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SCLEROSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030612466     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.764     Document Type: Article

References (49)

1. Babb TL, Brown WJ. Pathological findings in epilepsy. In: Engel JJ, ed. Surgical treatment of the epilepsies. New York: Raven Press, 1987:511-540.
2. Jackson GD, Connelly A, Duncan JS, Grünewald RA, Gadian DG. Detection of hippocampal pathology in intractable partial epilepsy: increased sensitivity with quantitative magnetic resonance T2 relaxometry. Neurology 1993;43:1793-1799.
3. Van Paesschen W, Sisodiya S, Connelly A, et al. Quantitative hippocampal MRI and intractable temporal lobe epilepsy. Neurology 1995;45:2233-2240.
4. Van Paesschen W, Connelly A, King MD, Jackson GD, Duncan JS. The spectrum of hippocampal sclerosis: a quantitative magnetic resonance imaging study. Ann Neurol 1997;41:41-51.
5. A receptor subtypes: autoradiographic comparison of GABA, benzodiazepine and convulsant binding sites in rat central nervous system. J Chem Neuroanat 1990;3:59-76.
6. 11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot 1984;35:973-976.
7. Henry TR, Frey KA, Sackellares JC, et al. In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy. Neurology 1993;43:1998-2006.
8. 18F-FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry 1993;56:615-621.
9. Koepp MJ, Richardson MP, Brooks DJ, et al. Cerebral benzodiazepine receptors in hippocampal sclerosis: an objective in vivo analysis. Brain 1996;119:1677-1687.
10. Gaillard WD, Bhatia S, Bookheimer SY, Fazilat S, Sato S, Theodore WH. FDG-PET and volumetric MRI in the evaluation of patients with partial epilepsy. Neurology 1995;45:123-126.
11. Semah F, Baulac M, Hasboun D, et al. Is interictal temporal hypometabolism related to mesial temporal sclerosis? A positron emission tomography/magnetic resonance imaging confrontation. Epilepsia 1995;36:447-456.
12. Johnson EW, de Lanerolle NC, Kim JH, et al. "Central" and "peripheral" bezondiazepine receptors: opposite changes in human epileptogenic tissue. Neurology 1992;42:811-815.
13. Burdette DE, Sakurai SY, Henry TR, et al. Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy. Neurology 1995;45:934-941.
14. Hand KSP, Bowery NG, Baird VH, et al. Central benzodiazepine receptor autoradiography in hippocampal sclerosis. Epilepsia 1996;37(Suppl. 5):43.
15. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979;3:299-308.
16. Müller Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain grey matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-583.
17. Meltzer CC, Zubieta JK, Links JM, Brakeman P, Stumpf, Frost JJ. MR-based correction for brain PET measurements for heterogenous grey matter radioactivity distribution. J Cereb Blood Flow Metab 1996;16:650-658.
18. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47: 454-461.
19. Labbé C, Fromment JC, Kennedy A, Ashburner J, Cinotti L. Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging. Alzheimer Dis Assoc Disord, 1996;10:141-170.
20. Wieser HG. The phenomenology of limbic seizures. In: Wieser HG, Speckmann EJ, Engel JJ, eds. The epileptic focus. London, Paris: Libbey, 1987;113-136.
21. Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30: 389-399.
22. Cook MJ, Fish DR, Shorvon SD, Straughan K, Stevens JM. Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. Brain 1992;115:1001-1015.
23. Jackson G, Berkovic S, Tress B, Kalnins R, Fabinyi GC, Bladin PF. Hippocampal sclerosis can be reliably detected by magnetic resonance imaging. Neurology 1990;40:1869-1875.
24. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17: 536-546.
25. Engel JJ. Outcome with respect to seizures. In: Engel JJ, ed. Surgical treatment of the epilepsies. New York: Raven Press, 1987:553-572.
26. Williams RW, Rakic P. Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J Comp Neurol 1988;278:344-352.
27. Lorente de No R. Studies on the structure of the cerebral cortex. II: Continuation of the study of the Ammonic system. J Psychol Neurol 1934;46:113-177.
28. Spinks TJ, Jones T, Bailey DL, et al. Physical performance of a new positron tomograph with retractable septa. IEEE Med Imag Conf Rec 1991;38:1313-1317.
29. 11C-Flumazenil PET study. Ann Neurol 1996;40: 188-198.
30. Jackson GD, Berkovic SF, Duncan JS, Connelly A. Optimizing the diagnosis of hippocampal sclerosis using MR imaging AJNR Am J Neuroradiol 1993;14:753-762.
31. Bailey DL. 3D acquisition and reconstruction in positron emission tomography. Ann Nucl Med 1992;6:121-130.
32. Friston KJ, Ashburner J, Poline JB, Frackowiak RSJ. Spatial registration and normalization of images. Human Brain Mapping 1995;2:165-189.
33. Cunningham VJ, Jones T. Spectral analysis of dynamic PET data. J Cereb Blood Flow Metab 1993;13:15-23.
34. Robb RA, Hanson DP. ANALYZE: a software system for biomedical image analysis. First Conference on Visualization in Biomedical Computing. Atlanta, 1990:507-518.
35. Hartigan JA. Clustering algorithms. New York: John Wiley, 1975.
36. Bland MJ, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;327:307-310.
37. Haycock KA, Roth J, Gagnon J, et al. Abacus Concepts, Stat-View. Berkeley, CA: Abacus Concepts, Inc., 1992.
38. Sezelies B. Weber-Luxenberger G, Pawlik G, et al. Focus detection in temporal lobe epilepsy by MRI coregistered quantitative flumazenil and FDG PET. Neuroimage 1996;3:109-118.
39. Meltzer CC, Leal JP, Mayberg HS, Wagner HJ, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990;14:561-570.
40. Margerison JHM, Corsellis JAN. Epilepsy and the temporal lobes. A clinical, electroencephalographic and neuropathological study of the brain in epilepsy. Brain 1966;89:479-530.
41. Connelly A, Jackson GD, Duncan JS, King MD, Gadian DG. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 1994;44:1411-1417.
42. 11C-Flumazenil positron emission tomography visualises frontal epileptogenic regions. Epilepsia 1995;36:1225-1232.
43. 11C-Flumazenil PET in temporal lobe epilepsy with normal or nondiagnostic MRI. Epilepsia 1996;37(Suppl. 4):S153.
44. 11C-Flumazenil PET reveals central benzodiazepine receptor binding abnormalities in partial epilepsy with normal MRI. Neurology 1996;46(Suppl 2):S122-123.
45. Savic I, Svanborg E, Thorell JO. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: a positron emission tomography study. Epilepsia 1996;37:236-244.
46. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial observations on the effect of gabapentin on brain GABA in patients with epilepsy. Ann Neurol 1996;39:95-99.
47. Leidermann DB, Balish M, Sato S, Theodore WH. Comparison of PET measurements of cerebral blood flow and glucose metabolism for the localization of human epileptic foci. Epilepsy Res 1992;13:153-157.
48. Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol 1991;30:663-672.
49. McDonald JW, Garofalo EA, Hood T, et al. Altered excitatory and inhibitory amino acid receptor binding in hippocampus of patients with temporal lobe epilepsy. Ann Neurol 1991;29: 529-541.